Drug Profile
PAC 1
Alternative Names: Procaspase activating compound 1; VO-100Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Vanquish Oncology
- Developer Genentech; Hoosier Cancer Research Network; University of Illinois at Chicago; Vanquish Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Caspase 3 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Uveal melanoma
- No development reported Anaplastic astrocytoma; Glioblastoma; Lymphoma
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Anaplastic-astrocytoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Anaplastic-astrocytoma(Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)